MTOR and cancer: ATP-competitive (catalytic) inhibitors of mTOR that can deactivate both mTORC1 and mTORC2 are currently used for some solid tumors as anti-cancer agents, and as immune-modulator after various organs transplantation to prevent virus associated nephropathy.